ExLibris header image
SFX Logo
Title: The endogenous cannabinoid anandamide potentiates interleukin-6 production by astrocytes infected with Theiler's murine encephalomyelitis virus by a receptor-mediated pathway
Source:

Febs Letters [0014-5793] Molina Holgado, Francisco yr:1998


Collapse list of basic services Basic
Full text
Full text available via Wiley Online Library Full Collection 2019
GO
Document delivery
Request document via Library/Bibliothek GO
Users interested in this article also expressed an interest in the following:
1. Cabral, G A A. "Cannabinoids inhibit LPS-inducible cytokine mRNA expression in rat microglial cells." GLIA 29.1 (2000): 58-69. Link to Full Text for this item Link to SFX for this item
2. Yiangou, Y. "Cannabinoid receptor CB-2 expression in activated microglia of multiple sclerosis and amyotrophic lateral sclerosis spinal cord." Journal of neurology, neurosurgery and psychiatry 75.8 (2004): 1226-1226. Link to Full Text for this item Link to SFX for this item
3. Ziring, D. "Formation of B and T cell subsets require the cannabinoid receptor CB2." Immunogenetics 58.9 (2006): 714-25. Link to Full Text for this item Link to SFX for this item
4. Correa, F. "Cannabinoid system and neuroinflammation: implications for multiple sclerosis." Neuroimmunomodulation 14.3-4 (2007): 182-7. Link to SFX for this item
5. Docagne, C. "The role of cannabinoid system on immune modulation: therapeutic implications on CNS inflammation." Mini reviews in medicinal chemistry 5.7 (2005): 671-5. Link to SFX for this item
6. Gong, Jian-Ping P. "Cannabinoid CB2 receptors: immunohistochemical localization in rat brain." Brain Research 1071.1 (2006): 10-23. Link to SFX for this item
7. Sirohi, B. "Epidemiology and outcomes research for MGUS, myeloma and amyloidosis." European journal of cancer 42.11 (2006): 1671-83. Link to SFX for this item
Select All Clear All

Expand list of advanced services Advanced
A service provided by the Library of the Wissenschaftspark Albert Einstein, Potsdam, Germany.
© 2005 SFX by Ex Libris Inc.